554723 Sigma-AldrichATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem
The differentiation-inducer all-trans-Retinoic Acid and the histone deacetylase inhibitor (HDI) Butyric Acid.
More>> The differentiation-inducer all-trans-Retinoic Acid and the histone deacetylase inhibitor (HDI) Butyric Acid. Less<<SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
Synonyme: 4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124, HDAC Inhibitor XV
Empfohlene Produkte
Übersicht
| Replacement Information |
|---|
Key Spec Table
| CAS # | Empirical Formula |
|---|---|
| 1037543-26-2 | C₃₁H₄₀O₄ |
Preis & Verfügbarkeit
| Bestellnummer | Verfügbarkeit | Verpackung | St./Pkg. | Preis | Menge | |
|---|---|---|---|---|---|---|
| 554723-25MG |
|
Kst.-Ampulle | 25 mg |
|
— |
| Description | |
|---|---|
| Overview | The differentiation-inducer all-trans-Retinoic Acid (ATRA; Cat. No. 554720) and the histone deacetylase inhibitor (HDI) Butyric Acid (BA; Cat. No. 567430) are incorporated chemically via a benzyl ester linkage into a single more permeant mutual prodrug (MP) to facilitate their cellular uptake and to better synergize their cancer killing potency. The growth inhibitions of PC-3 and MDA-MB-231 by the MP (IC50 = 1.02 and 0.01 µM, respectively) are much superior to those achieved by separate (IC50 = 7.6 and 10.85 µM, respectively, with ATRA; IC50 = 72.44 and >1000 µM, respectively, with BA) or combined dosing of ATRA/BA (55% vs. 30% PC-3 growth inhibition by 10 µM MP vs. co-treatment of 10 µM each of ATRA & BA). At 37°C, VNLG/124 is completely converted to ATRA and BA within an hour in fresh murine plasma, but is otherwise stable for more than 24 hours in the absence of esterase activity in 20 mM PBS. |
| Catalogue Number | 554723 |
| Brand Family | Calbiochem® |
| Synonyms | 4-(Butanoyloxymethyl)phenyl-(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoate, VNLG/124, HDAC Inhibitor XV |
| References | |
|---|---|
| References | Gediya, L.K., et al. 2008. J. Med. Chem. 51, 3895. |
| Product Information | |
|---|---|
| CAS number | 1037543-26-2 |
| Form | Yellow solid |
| Hill Formula | C₃₁H₄₀O₄ |
| Chemical formula | C₃₁H₄₀O₄ |
| Structure formula Image | |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Purity | ≥95% by HPLC |
| Physicochemical Information |
|---|
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Bestellnummer | GTIN |
| 554723-25MG | 04055977193138 |
Documentation
ATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem SDB
| Titel |
|---|
ATRA-BA Hybrid - CAS 1037543-26-2 - Calbiochem Analysenzertifikate
| Titel | Chargennummer |
|---|---|
| 554723 |
Literatur
| Übersicht |
|---|
| Gediya, L.K., et al. 2008. J. Med. Chem. 51, 3895. |
Technische Informationen
| Titel |
|---|
| White Paper - The Message in the Marks: Deciphering Cancer Epigenetics |
| Datenblatt | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
|